More on vitamin D and COVID-19

May 14, 2020

The evidence is growing that those with low vitamin D levels are at a higher risk for respiratory infections, including COVID-19. However, purists argue that we need more evidence and better evidence from randomized trials. This is quite irresponsible considering that we have so much correlational data and that the risk of taking vitamin D is minuscule. You can read some of the debates on this question in the recent issue of the Irish Medical Journal.

As I mentioned in a recent post, it is important to keep your vitamin D level not only in the normal range, which in most laboratories is between 30 and 100, but at least in the middle of this range.

One piece of supporting evidence is the fact that patients with multiple sclerosis (MS) whose vitamin D level is in the bottom quartile of the normal range are four times more likely to have a flare-up of their MS than those in the top quartile. Another MS study showed “…profound association of 25(OH)D levels with MRI measures of disease activity and progression” Those with vitamin D deficiency were also found to have higher risk of developing Alzheimer’s disease.

The above-mentioned evidence is not necessarily transferable to respiratory infections, however, multiple sclerosis is an autoimmune inflammatory condition, while Alzheimer’s has an inflammatory component and it is possible that inflammation could be where vitamin D exerts its beneficial effect.

So the debates need to end and everyone should take at least 50 mcg (2,000 units) of vitamin D. An important fact to keep in mind is that some people do not absorb vitamin D well so if you were found to be deficient, it is a good idea to recheck your level since you may need to increase the dose.

Written by
Alexander Mauskop, MD
Continue reading
August 8, 2026
Sugar is bad for your brain, even before you are born.
Sugar consumed in the first two years of life increases the risk of dementia.
Read article
August 6, 2026
Research
An Old Medicine that Could Make Brain Stimulation Work Better for Depression and Other Neurological Conditions
A 2022 clinical trial from the University of Calgary found that adding low‑dose D‑cycloserine (DCS), a partial NMDA‑receptor agonist, to intermittent theta‑burst stimulation (iTBS) significantly increased response and remission rates in depression without serious side effects. Early follow‑up data suggest that timing, dose, and drug levels matter, and raise the possibility that this DCS‑TMS approach could eventually be applied to other neurological conditions—such as migraine, postconcussion syndrome, brain fog, and long COVID
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe